Over 2000 Employees Fired Overnight as Trump Administration Restructures Health Agencies
On February 14, the Trump administration initiated a sweeping layoff affecting more than 2000 employees in key health agencies, including the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). This drastic move came on the first day of Robert F. Kennedy Jr.'s tenure as Secretary of Health and Human Services (HHS).
The initial layoff list indicated that approximately 1500 NIH employees and 1269 CDC employees would be affected. However, recent updates suggest that the number of layoffs at NIH has been adjusted to 1165. Among those terminated are many grassroots researchers, recently hired scientists, and department heads. This mass firing has raised significant concerns about the continuity of ongoing clinical trials, as the dismissal of clinical researchers could halt numerous projects.
Additionally, the Advanced Research Projects Agency for Health (ARPA-H), established just three years ago, has also seen its first director and a majority of staff let go. The agency was designed to fund high-risk, high-reward research with an annual budget of $1.5 billion. The layoffs extend beyond HHS, with reports indicating that the Environmental Protection Agency (EPA) may face similar cuts, potentially impacting 20% of its scientific workforce.
This restructuring raises alarms about the future of public health initiatives in the U.S., especially in areas critical for pandemic response and disease prevention.
Looking for chemical products? Let suppliers reach out to you!
2026-06-29
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
Recommend Reading
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
Vertex Shares Plunge 14.4 Percent After Pain Drug Trial Misses Key Target and Study Halt
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
2025 ECHEMI Global Buyer Match Event
-
A $25 Billion “Mega Merger” Is Born: How the AkzoNobel × Axalta Deal Rewrites Global Coatings Power
-
China Shenhua Plans Major Asset Injection with 13 Companies Involved Stock Trading Halted for Up to 10 Days
-
FDA Dye Tracker Raises Reformulation Pressure Across Food Brands
-
Weak Demand Leads to a Decline in n-Butanol Prices in China